{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:35:38Z","timestamp":1792985738867,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104877","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:35:19Z","timestamp":1754433319000},"page":"104877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cardiovascular safety outcomes of chronic lymphocytic leukemia treatments: A systematic and targeted literature review"],"prefix":"10.1016","volume":"215","author":[{"given":"Yen-Chou","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan K.","family":"Barqawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace E.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinenye","family":"Chukwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal P.","family":"O\u2019Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.critrevonc.2025.104877_bib1","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104877_bib2","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","article-title":"Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC study)","volume":"21","author":"Abrisqueta","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104877_bib3","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jth.14475","article-title":"Risk of thromboembolic and bleeding outcomes following hematological cancers: a danish population-based cohort study","volume":"17","author":"Adelborg","year":"2019","journal-title":"J. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104877_bib4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104877_bib5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104877_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001049","article-title":"High incidence of atrial fibrillation in patients treated with ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open Heart"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104877_bib7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJM199308263290902","article-title":"Racial differences in the incidence of cardiac arrest and subsequent survival","volume":"329","author":"Becker","year":"1993","journal-title":"CPR Chic. Proj. N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104877_bib8","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.104877_bib9","unstructured":"Brukinsa [package insert]. 2023. BeiGene USA, Inc, San Mateo, CA."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104877_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104877_bib11","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104877_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med"},{"issue":"31","key":"10.1016\/j.critrevonc.2025.104877_bib13","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase 3 trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104877_bib14","unstructured":"Calquence [package insert]. 2022. AstraZeneca Pharmaceuticals, Wilmington, DE."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104877_bib15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104877_bib16","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ctrv.2012.02.006","article-title":"A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia","volume":"38","author":"Cheng","year":"2012","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104877_bib17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jacc.2004.06.029","article-title":"Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. Community","volume":"44","author":"Chugh","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104877_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s44228-022-00015-5","article-title":"FIRE study: real-world effectiveness and safety of ibrutinib in clinical practice in patients with CLL and MCL","volume":"4","author":"Dartigeas","year":"2022","journal-title":"Clin. Hematol. Int."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104877_bib19","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S2352-3026(17)30235-1","article-title":"Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study","volume":"5","author":"Dartigeas","year":"2018","journal-title":"Lancet Haematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104877_bib20","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.clinthera.2020.08.017","article-title":"Comparative efficacy of acalabrutinib in frontline treatment of chronic lymphocytic leukemia: a systematic review and network meta-analysis","volume":"42","author":"Davids","year":"2020","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104877_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaccao.2023.02.001","article-title":"Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients","volume":"5","author":"Diamond","year":"2023","journal-title":"Jacc. CardioOncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104877_bib22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104877_bib23","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104877_bib24","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104877_bib25","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/j.clml.2020.02.013","article-title":"Novel targeted therapies for chronic lymphocytic leukemia in elderly patients: a systematic review","volume":"20","author":"Farooqui","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104877_bib26","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCRESAHA.121.318259","article-title":"Vascular impact of cancer therapies: the case of BTK (Bruton tyrosine kinase) inhibitors","volume":"128","author":"Fleming","year":"2021","journal-title":"Circ. Res."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104877_bib27","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1080\/10428194.2020.1795159","article-title":"Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"61","author":"Fraser","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104877_bib28","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104877_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator's choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104877_bib30","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104877_bib31","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104877_bib32","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage binet a high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104877_bib33","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104877_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol."},{"issue":"9980","key":"10.1016\/j.critrevonc.2025.104877_bib35","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104877_bib36","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/cam4.1337","article-title":"Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study","volume":"7","author":"Huang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2025.104877_bib37","unstructured":"Imbruvica [package insert]. 2023. Pharmacyclics LLC, Janssen Biotech, Inc., Sunnyvale, CA, Horsham, PA."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104877_bib38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2015-04-585067","article-title":"Initial treatment of CLL: integrating biology and functional status","volume":"126","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104877_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s44228-022-00020-8","article-title":"Effectiveness and safety of ibrutinib for chronic lymphocytic leukemia in routine clinical practice: 3-year follow-up of the Belgian ibrutinib Real-World data (BiRD) study","volume":"4","author":"Janssens","year":"2022","journal-title":"Clin. Hematol. Int."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104877_bib40","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cancers15041018","article-title":"A history of targeted therapy development and progress in novel-novel combinations for chronic lymphocytic leukemia (CLL)","volume":"15","author":"Karr","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104877_bib41","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104877_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2014.11.004","article-title":"A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia","volume":"41","author":"Ladyzynski","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104877_bib43","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104877_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104877_bib45","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1002\/ajh.26558","article-title":"Cardiovascular disease in patients with chronic lymphocytic leukemia: a Swedish nationwide register study with matched comparators","volume":"97","author":"Larsson","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104877_bib46","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2011-07-365437","article-title":"Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial","volume":"119","author":"Lepretre","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104877_bib47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jha2.638","article-title":"A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States","volume":"4","author":"Mato","year":"2023","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104877_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2017.1394554","article-title":"Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia","volume":"19","author":"Mato","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104877_bib49","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/hon.3126","article-title":"Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study","volume":"41","author":"Mattiello","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104877_bib50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clml.2020.10.012","article-title":"Comparison between venetoclax-based and bruton tyrosine kinase inhibitor-based therapy as upfront treatment of chronic lymphocytic leukemia (CLL): a systematic review and network meta-analysis","volume":"21","author":"Molica","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.104877_bib51","article-title":"Comparative safety of novel targeted therapies in relapsed\/refractory chronic lymphocytic leukemia: a network meta-analysis","volume":"16","author":"Monica","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104877_bib52","article-title":"Network meta-analysis of novel targeted therapies for relapsed\/refractory chronic lymphocytic leukemia","volume":"16","author":"Monica","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104877_bib53","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104877_bib54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104877_bib55","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104877_bib56","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/bloodadvances.2023011641","article-title":"Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib","volume":"8","author":"Moslehi","year":"2024","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104877_bib57","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3109\/10428194.2014.893306","article-title":"Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia","volume":"55","author":"Mulligan","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104877_bib58","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104877_bib59","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1016\/j.clml.2022.07.004","article-title":"Real-world persistence and time to next treatment with ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma including patients at high risk for atrial fibrillation or stroke","volume":"22","author":"Narezkina","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.104877_bib60","unstructured":"National Institutes of Health. SEER Cancer Stat Facts: Leukemia - Chronic Lymphocytic Leukemia. 2024. <\u3008https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html\u3009>. Accessed May 17, 2024."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104877_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15071996","article-title":"Efficacy and safety of bruton tyrosine kinase inhibitor monotherapy compared with combination therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma: a systematic review and meta-analysis","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104877_bib62","doi-asserted-by":"crossref","first-page":"9775","DOI":"10.1038\/s41598-023-36279-x","article-title":"Efficacy and safety of add-on anti-CD20 monoclonal antibody to bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis","volume":"13","author":"Nguyen","year":"2023","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104877_bib63","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/CJI.0000000000000471","article-title":"Efficacy and safety of bruton tyrosine kinase inhibitor plus anti-CD20 antibody therapy compared with chemoimmunotherapy as front-line treatment for chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Nguyen","year":"2023","journal-title":"J. Immunother."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104877_bib64","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/10428194.2017.1375101","article-title":"Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed\/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials","volume":"59","author":"Pu\u0142a","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104877_bib65","first-page":"S44","article-title":"Atrial fibrillation and bleeding in patients with chronic lymphocytic leukemia treated with ibrutinib in the veterans health administration","volume":"37","author":"Rasmussen","year":"2020","journal-title":"Fed. Pr."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104877_bib66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamaoncol.2020.5742","article-title":"Ibrutinib's cardiotoxicity-An opportunity for postmarketing regulation","volume":"7","author":"Ratain","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104877_bib67","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-018-0626-0","article-title":"Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study","volume":"11","author":"Reda","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104877_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24129930","article-title":"Molecular-biology-driven frontline treatment for chronic lymphocytic leukemia: a network meta-analysis of randomized clinical trials","volume":"24","author":"Rizzuto","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104877_bib69","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/10428194.2016.1233536","article-title":"Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial","volume":"58","author":"Robak","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"9499","key":"10.1016\/j.critrevonc.2025.104877_bib70","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(05)67702-1","article-title":"Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study)","volume":"366","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104877_bib71","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104877_bib72","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104877_bib73","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104877_bib74","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104877_bib75","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104877_bib76","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104877_bib77","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","article-title":"Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial","volume":"8","author":"Sharman","year":"2021","journal-title":"Lancet Haematol."},{"issue":"10232","key":"10.1016\/j.critrevonc.2025.104877_bib78","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104877_bib79","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1080\/10428194.2020.1811271","article-title":"Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis","volume":"61","author":"Sheng","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104877_bib80","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s12325-016-0398-2","article-title":"A systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia","volume":"33","author":"St\u00e4dler","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2025.104877_bib81","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clin. Res. Ed. )"},{"key":"10.1016\/j.critrevonc.2025.104877_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104428","article-title":"Safety profile of first-line targeted therapies in elderly and\/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). a systematic review and network meta-analysis","volume":"201","author":"Sto\u017cek-Tutro","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104877_bib83","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0895-4356(03)00210-5","article-title":"The incidence of sudden cardiac death in the general population","volume":"57","author":"Straus","year":"2004","journal-title":"J. Clin. Epidemiol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104877_bib84","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104877_bib85","article-title":"Distinct age-related clinical features and risk assessment in Chinese with chronic lymphocytic leukemia","volume":"12","author":"Tian","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104877_bib86","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/hon.2655","article-title":"A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia","volume":"37","author":"Visentin","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104877_bib87","unstructured":"Wells, G.A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., 2014. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. <\u3008https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\u3009> (accessed 12 February 2024."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104877_bib88","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/17474086.2022.2110062","article-title":"Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review","volume":"15","author":"Wen","year":"2022","journal-title":"Expert Rev. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104877_bib89","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/cer-2017-0086","article-title":"Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis","volume":"7","author":"Xu","year":"2018","journal-title":"J. Comp. Eff. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104877_bib90","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:28:58Z","timestamp":1792985338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":90,"alternative-id":["S1040842825002653"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104877","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular safety outcomes of chronic lymphocytic leukemia treatments: A systematic and targeted literature review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104877"}}